Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial HypertensionBusiness Wire • 05/16/25
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All ComersBusiness Wire • 05/15/25
FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)Business Wire • 05/14/25
Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)Seeking Alpha • 05/14/25
Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025Business Wire • 05/13/25
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to knowCNBC • 05/12/25
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - YetSeeking Alpha • 05/12/25
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug CostsZacks Investment Research • 05/12/25
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior PrincipalGlobeNewsWire • 05/12/25